MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2022 International Congress

    USE OF NIGHT TIME CONTINUOUS SUBCUTANEOUS INFUSION OF APOMORPHINE (NCSAI) IN ADVANCED PARKINSON’S DISEASE: A SERIES OF 37 CASES.

    AK. Vargas Mendoza, B. López López, M. Díaz Castela, J. Molina Gil, P. Zunzunegui Arroyo, A. Criado Antón, ME. Suárez Sanmartín, C. García Fernández (Oviedo, Spain)

    Objective: The aim of this study is to evaluate the feasibility, efficacy and safety of NCSAI administration in patients with Advanced Parkinson disease (APD). Background:…
  • 2022 International Congress

    Expanding the armamentarium of clinical use of apomorphine in movement disorders.

    S. Bansal, JR. Chai, M. Jog (London, Canada)

    Objective: To demonstrate the use of subcutaneous(SC) apomorphine injections in suspected untreated dopamine responsive conditions. Background: Apomorphine is a dopamine agonist historically used in dopamine…
  • 2022 International Congress

    Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Incremental Motor Improvement Observed with Increasing Doses

    S. Isaacson, I. Zhang, E. Pappert, A. Bowling (Boca Raton, USA)

    Objective: Evaluate magnitude of motor improvement with increasing doses of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease (PD) and OFF episodes. Background: Identifying…
  • 2022 International Congress

    Use of apomorphine infusion pump in the elderly population : a 5 years follw up study on efficacy, safety and tolerability in a cohort bases study

    C. Borrue- Fernandez, M. Mata, C. Jimeno, M. Almarcha (San Sebastian Reyes, Spain)

    Objective: Evaluate the efficacy, tolerability and safety of subcutaneous apomorphine infusion in elderly patients with advanced Parkinson's disease in a five years follow up cohort. Background: Continuous infusion by subcutaneous apomorphine pump has…
  • 2022 International Congress

    May apomorphine be helpful for the axial symptoms of Parkinson’s Disease?

    A. Alonso-Canovas, P. Perez Torre, G. Sanchez Diez, A. Patiño Paton, N. Gonzalez, I. Parees Moreno, JC. Martinez Castrillo (Madrid, Spain)

    Objective: To assess the effect of continuous subcutaneous infusion of apomorphine on axial symptoms of Parkinson Disease. Background: Axial symptoms of Parkinson’s Disease may be…
  • 2022 International Congress

    Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…
  • 2022 International Congress

    Apomorphine Hydrochloride Injection Treatment Initiations in the Presence and Absence of an Antiemetic in People with Parkinson Disease

    C. Happel, M. Grall, B. Lujan, A. Formella (Rockville, USA)

    Objective: To provide real-world experience regarding apomorphine treatment initiations with or without concomitant antiemetic prophylaxis. Background: Apomorphine hydrochloride (apo) injection, administered subcutaneously, is an “on-demand’…
  • 2022 International Congress

    Adverse drug reactions to apomorphine: a worldwide pharmacovigilancedatabase analysis

    M. Auffret, C. Le Corre, LM. Scailteux, M. Vérin, E. Polard (Rennes, France)

    Objective: To determine the safety profile of apomorphine (expected vs. new signals), regardless of the indication and route of administration. Background: Adverse drug reactions (ADR)…
  • 2022 International Congress

    Therapy resistant tremor in Parkinson’s disease. Satisfying an unmet need.

    SW. Pedersen, L. Johannsen (Frederiksberg, Denmark)

    Objective: Investigation on Parkinson's patients with therapy-resistant tremor usingapomorphine-pen injection for alleviation of resting tremor. Background: In Parkinson’s disease one of the major disturbing symptoms…
  • 2022 International Congress

    Efficacy of Apomorphine Sublingual Film Versus Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease

    F. Stocchi, O. Rascol, W. Poewe, R. Chaudhuri, J. Kassubek, L. Lopez Manzanares, V. Leta, I. Zhang, A. Bowling, S. Wu, E. Pappert (Rome, Italy)

    Objective: Evaluate efficacy and patient satisfaction associated with apomorphine sublingual film (SL-APO) vs subcutaneous apomorphine (SC-APO) for the treatment of OFF episodes in patients with…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley